3 unknown, 2 completed, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 2, Completed 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Terminated 1, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Ocular Graft-versus-host Disease: new trials by email Literature Review of Ocular Graft-versus-host Disease trials Research Report on Ocular Graft-versus-host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) rhPRG4 - Ocular Graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Lubris Bio Pty Ltd | 3 | 2025-02-14 | 2026-01-21 |
| Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies Rare Diseases, Aniridia | Unknown | IRCCS Ospedale San Raffaele | 274 | 2024-05-01 | 2024-05-14 | |
| Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT Cyclosporine ophthalmic solution 0.1%, Tacrolimus ophthalmic ointment 0.03% - Ocular Graft-versus-host Disease | Phase 1 / Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 60 | 2023-08-01 | 2024-04-08 |
| The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease Lifitegrast 5% Ophthalmic Solution, Placebo - Graft-versus-host-disease, Ocular Graft-versus-host Disease | Early Phase 1 | Completed | Richard W Yee, MD | 30 | 2022-10-22 | 2024-07-15 |
| Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease Pro-ocular™ Topical Gel 1%, Placebo - Ocular Graft-versus-host Disease | Phase 2 / Phase 3 | Unknown | Glia, LLC | 44 | 2021-04-15 | 2023-03-24 |
| Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease Allogeneic platelet lysate eye drops - Ocular Graft-versus-host Disease | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 38 | 2021-04-01 | 2024-12-04 |
| Vigamox Treatment for Ocular Graft-Versus-Host Disease Vigamox, Placebo - Ocular Graft-versus-host Disease | Phase 2 | Withdrawn | Washington University School of Medicine | 2020-06-15 | 2023-08-08 |
Dry Eye Syndromes (2) · Graft vs Host Disease (2) · Aniridia (1) · Bronchiolitis Obliterans Syndrome (1) · Corneal Neovascularization (1) · Ectrodactyly-cleft lip-palate syndrome (1) · Lacerations (1) · Limbal Stem Cell Deficiency (1) · Pemphigoid, Benign Mucous Membrane (1) · Rare Diseases (1)
Eye Diseases (3) · Immune System Diseases (3) · Lacrimal Apparatus Diseases (2) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Conjunctival Diseases (1) · Corneal Diseases (1) · Disease Attributes (1) · Eye Abnormalities (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1)
Moxifloxacin (1) · Ophthalmic Solutions (1) · lifitegrast (1)
Glia, LLC (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · IRCCS Ospedale San Raffaele (1) · Lubris Bio Pty Ltd (1) · Richard W Yee, MD (1) · St. Petersburg State Pavlov Medical University (1) · Washington University School of Medicine (1)
United States (2) · Australia (1) · Mexico (1) · Russia (1)
Todd Margolis, M.D., Ph.D. (1)